Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alliance Pharma to delay release of 2023 results

(Sharecast News) - Shares in Alliance Pharma slipped on Friday after the healthcare company said that its full-year results would be delayed. Alliance, which had been due to publish its preliminary results for 2023 on 9 April, said figures are now expected to be released on 23 April.

"The group's auditor has determined that the volume of work required to complete the audit has exceeded its original expectations, necessitating a short delay in the reporting timetable," the statement said.

Nevertheless, the company assured that details provided in its latest trading update in January "remain accurate".

Alliance has already reported revenues of £182.7m for 2023, up 6% on the previous year, while underlying profits were said to be in line with market expectations.

The stock was down 2% at 37.66p by 0803 BST.

Share this article

Related Sharecast Articles

Frontier IP's Alusid launches another range with Topps Tiles
(Sharecast News) - Frontier IP announced on Friday that its portfolio company Alusid has launched its first range of floor tiles through Parkside Architectural Tiles, the commercial division of Topps Tiles.
Enteq appoints new head of finance
(Sharecast News) - Energy service engineering and technology company Enteq announced the appointment of Amir Absoud as its head of finance on Friday, to immediately succeed the current chief financial officer, Mark Ritchie.
EnSilica to raise £0.3m through retail offer
(Sharecast News) - EnSilica announced a retail offer through the Winterflood Retail Access Platform (WRAP) on Friday, to raise up to £0.3m.
Recurring revenue, adjusted earnings rise for Pulsar Group
(Sharecast News) - Audience intelligence software specialist Pulsar Group said in its final results on Friday that its annualised recurring revenue (ARR) increased £2.7m, a significant improvement from the flat performance in the prior financial year.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.